CN1195546A - Medicine for curing angiocardiopathy and cerebrovascular disease - Google Patents

Medicine for curing angiocardiopathy and cerebrovascular disease Download PDF

Info

Publication number
CN1195546A
CN1195546A CN98101465A CN98101465A CN1195546A CN 1195546 A CN1195546 A CN 1195546A CN 98101465 A CN98101465 A CN 98101465A CN 98101465 A CN98101465 A CN 98101465A CN 1195546 A CN1195546 A CN 1195546A
Authority
CN
China
Prior art keywords
medicine
radix
cerebrovascular disease
root
blood
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN98101465A
Other languages
Chinese (zh)
Other versions
CN1056309C (en
Inventor
杨允钊
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CN98101465A priority Critical patent/CN1056309C/en
Publication of CN1195546A publication Critical patent/CN1195546A/en
Application granted granted Critical
Publication of CN1056309C publication Critical patent/CN1056309C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Landscapes

  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to a pure Chinese medicine preparation with the functions of promoting circulation of blood and removing blood stasis, eliminating impediment and resolving masses, invigorating brain and enhancing intelligence, tonifying and building up body for curing angiocardiopathy and cerebrovascular diseases, including organ injury, coronary heart disease and polycythemia caused by hypoxia. Its prescription consists of (wt%) rhodiola root 10-50%, sal ammoniac 5-20%, rubia root 5-30%, tortoise plastron 3-20%, red peony root 3-15%, ground beetle 3-15%, belamcanda rhizome 3-15%, cinnamom twig 3-15% and hornet nest 3-15%. It is non-toxic, has no side effect and its clinical effective rate is up to 91.18%.

Description

A kind of medicine for the treatment of cardiovascular and cerebrovascular disease
The invention belongs to a kind of Chinese herbal medicine, relate in particular to a kind of medicine for the treatment of cardiovascular and cerebrovascular disease.
The medicine of existing cardio-cerebralvascular such as Isosorbide-5-Mononitrate, SUXIAO JIUXIN WAN, nitroglycerin etc. at relief of symptoms, improve aspects such as circulating function state and truly have certain curative effect, but often cause the multiple organ injury threat to life because of comprehensive factor because of cardiovascular and cerebrovascular disease.The said medicine curative effect is single, to the cardiovascular and cerebrovascular disease effect do not continue, drug resistance fast, can only be interrupted intermittently medication, SM for a long time can not be satisfactory to the multiple organ injury effect.
The purpose of this invention is to provide a kind of medicine for the treatment of cardiovascular and cerebrovascular disease, existing clinical heart and brain pipe disease medicament curative effect is single to solve, effect not lastingly, chemical sproof shortcoming fast, it has better therapeutic effect to the damage of many internal organs such as the liver that caused by heart disease, lung, spleen, kidney, and nontoxic, have no side effect.
The present invention is achieved in that its prescription (percentage by weight) is:
Radix Rhodiolae 10-50% Sal Ammoniacus 5-20% Radix Rubiae 5-30%
Carapax et Plastrum Testudinis 3-20% Radix Paeoniae Rubra 3-15% eupolyphaga 3-15%
Rhizoma Belamcandae 3-15% Ramulus Cinnamomi 3-15% Nidus Vespae 3-15%
Wherein optimum formula (percentage by weight) is:
Radix Rhodiolae 20-35% Sal Ammoniacus 7-15% Radix Rubiae 10-20%
Carapax et Plastrum Testudinis 5-15% Radix Paeoniae Rubra 5-10% eupolyphaga 5-10%
Rhizoma Belamcandae 5-10% Ramulus Cinnamomi 5-10% Nidus Vespae 5-10%
Medicine provided by the invention is according to theory of Chinese medical science, in conjunction with the doctor trained in Western medicine viewpoint, connect each other according to each internal organs of human body, complementary organic conception, newly achieve in conjunction with modern medicine, screen through repeated clinical practice, the pure Chinese medicinal preparation of preparation, has blood circulation promoting and blood stasis dispelling, the blood stasis dispelling eliminating stagnation, remove that humidifying is turbid, strengthening the body resistance, regulate the flow of vital energy nourish blood, nourishing the brain and improving intelligence, nourishing and fit keeping function, contain tens of seed amino acids (wherein 7 kinds of human bodies can not synthesize), the trace element that multiple human body is necessary, high energy protein and abundant plant amedica natural activity.It is many that it contains active ingredient, therapeutical effect multipath, therapeutic mechanism many-side; histiocyte and ultrastructure to body are unusual, have general protective effect, the energy expansion artery; microcirculation improvement; the adjusting smooth muscle is releived, and improves blood oxygen pressure, blood viscosity lowering; regulate cellular sodium, calcium ion overload load; enzyme is planted when reducing the conscience disease, promotes protein synthesis, recovers the conscience function.Medicine of the present invention can be treated coronary heart disease, angina cordis, arteriosclerosis, hemiplegia, have hepatitis B treating, recover liver function, hepatosplenomegaly person can soften retraction, can treat pulmonary congestion, pulmonary edema, high height above sea level and hypoxia induced acute lung injury had significantly prevent effect, the multiple organ injury that causes because of cardiovascular and cerebrovascular disease is had the positive therapeutic effect.Studies show that through clinical real inspection the clinical total effective rate of medicine of the present invention reaches more than 91.18%, and nontoxic, have no side effect.
Medicine of the present invention shows through animal experiment; this medicine has a general protective effect unusually to the histiocyte of body and ultrastructure aspect; expansion artery is arranged; improve blood oxygen pressure; resisting fatigue, reduction platelet adhesion and blood fat; improve super oxygen dismutase (SOD) quantity and its activity, promote cell regeneration, regulate the organism physiology disorder to normal conversion.
Medicine of the present invention shows through immunologic function test, can strengthen mononuclear-macrophage phagocytic function, regulates immunity of organism, and the enhancing body resistance against diseases can make the thymosin secretion increasing, the lymphocyte number of reaching maturity is increased.
Medicine of the present invention shows through 102 routine coronary heart disease clinical observations, patients with coronary heart disease had good curative effect, total effective rate reaches 91.18%, and it is particularly outstanding aspect common sympton such as alleviate uncomfortable in chest, chest pain, cardiopalmus, breathe hard, attack times is reduced, shorten the persistent period, have no adverse reaction between the operating period, the effect of this medicine rapidly, lastingly.
Medicine of the present invention shows through high height above sea level district hypoxia test, have improve blood oxygen pressure, anti-hypoxia, resisting fatigue, antitoxin, improve the work capacity of body on the plateau, make it possess the adaptability of anoxia enduring, can significantly suppress anoxia synthesizing to PAMC propagation and DNA, prevent after the anoxia pulmonary hypertension and form effect, can make with arachidonic acid generation and penetrate product TXB 2, 6-KetoPGFla is that the strong material of releiving that shrinks of blood vessel of representative is subjected to significant inhibition, and maintains low-level from start to finish.
Medicine of the present invention shows through toxicological test, and this medicine is nontoxic, have no side effect,
The processing technology of medicine of the present invention is a common process, can be made into various dosage forms such as oral liquid, capsule, tablet, powder.
Further specify the present invention below in conjunction with embodiment.
Embodiment 1, and its prescription is (percentage by weight):
Radix Rhodiolae 25% Sal Ammoniacus 9% Radix Rubiae 20%
Carapax et Plastrum Testudinis 10% Radix Paeoniae Rubra 8% eupolyphaga 7%
Rhizoma Belamcandae 7% Ramulus Cinnamomi 7% Nidus Vespae 7%
Make tablet; this medicine has good efficacy to patients with coronary heart disease; and alleviate uncomfortable in chest, chest pain, cardiopalmus, common sympton aspect such as breathe hard are particularly outstanding; the angina pectoris attacks number of times is reduced; persistent period shortens, and ischaemic ECG change is improved, the protection myocardial function; anti-hypoxia, resisting fatigue, the may command symptomatic recurrence.
Embodiment 2, and its prescription is (percentage by weight):
Radix Rhodiolae 45% Sal Ammoniacus 5% Radix Rubiae 15%
Carapax et Plastrum Testudinis 5% Radix Paeoniae Rubra 10% eupolyphaga 5%
Rhizoma Belamcandae 5% Ramulus Cinnamomi 5% Nidus Vespae 5%
Make oral liquid, this medicine can be corrected under high height above sea level district and the low-oxygen environment body tissue organ, brain, the heart, lung, kidney, gastral influence, can improve blood oxygen pressure, to erythrocytosis, the blood viscosity height, vascular resistance is big, slow blood flow, hyperlipidemia, pulmonary hypertension organizes diseases such as congestion and edema that the positive therapeutic effect is arranged.
Embodiment 3, and its prescription is (percentage by weight):
Radix Rhodiolae 15% Sal Ammoniacus 5% Radix Rubiae 10%
Carapax et Plastrum Testudinis 10% Radix Paeoniae Rubra 10% eupolyphaga 15%
Rhizoma Belamcandae 10% Ramulus Cinnamomi 10% Nidus Vespae 15%
Make capsule, the multiple organ injury of this medicine to causing, acute lung edema because of cardiovascular and cerebrovascular disease, anoxia, wound, the general toxic reaction syndrome that infects mediation has well prevents effect, improve the immunocompetence of body, reduce the dangerous hurried course of disease, reduce mortality rate.
In this medicine composition, as add an amount of Radix Ginseng and vitamin medicaments, various types of altitude sickness are also had certain therapeutical effect.

Claims (2)

1, a kind of medicine for the treatment of cardiovascular and cerebrovascular disease is characterized in that its pharmaceutical formulation (percentage by weight):
Radix Rhodiolae 10-50% Sal Ammoniacus 5-20% Radix Rubiae 5-30%
Carapax et Plastrum Testudinis 3-20% Radix Paeoniae Rubra 3-15% eupolyphaga 3-15%
Rhizoma Belamcandae 3-15% Ramulus Cinnamomi 3-15% Nidus Vespae 3-15%
2, a kind of medicine for the treatment of cardiovascular and cerebrovascular disease according to claim 1 is characterized in that the optimum formula of its medicine is:
Radix Rhodiolae 20-35% Sal Ammoniacus 7-15% Radix Rubiae 10-20%
Carapax et Plastrum Testudinis 5-15% Radix Paeoniae Rubra 5-10% eupolyphaga 5-10%
Rhizoma Belamcandae 5-10% Ramulus Cinnamomi 5-10% peak room 5-10%
CN98101465A 1998-05-11 1998-05-11 Medicine for curing angiocardiopathy and cerebrovascular disease Expired - Fee Related CN1056309C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN98101465A CN1056309C (en) 1998-05-11 1998-05-11 Medicine for curing angiocardiopathy and cerebrovascular disease

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN98101465A CN1056309C (en) 1998-05-11 1998-05-11 Medicine for curing angiocardiopathy and cerebrovascular disease

Publications (2)

Publication Number Publication Date
CN1195546A true CN1195546A (en) 1998-10-14
CN1056309C CN1056309C (en) 2000-09-13

Family

ID=5216714

Family Applications (1)

Application Number Title Priority Date Filing Date
CN98101465A Expired - Fee Related CN1056309C (en) 1998-05-11 1998-05-11 Medicine for curing angiocardiopathy and cerebrovascular disease

Country Status (1)

Country Link
CN (1) CN1056309C (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1081465C (en) * 1999-03-08 2002-03-27 张早华 Rhodiola rosea injection for treating angina pectoris of coronary heart disease
CN100366270C (en) * 2003-04-22 2008-02-06 杨允钊 Medicine for curing cardiovascular and cerebrovascular diseases

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1079158A (en) * 1993-03-18 1993-12-08 吉林省东丰制药厂 Compound oral liquid preparation of alpine rhodiola root and preparation technology thereof
CN1106291A (en) * 1994-02-04 1995-08-09 白玛加措 Tibetan drug and its prepn.

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1081465C (en) * 1999-03-08 2002-03-27 张早华 Rhodiola rosea injection for treating angina pectoris of coronary heart disease
CN100366270C (en) * 2003-04-22 2008-02-06 杨允钊 Medicine for curing cardiovascular and cerebrovascular diseases

Also Published As

Publication number Publication date
CN1056309C (en) 2000-09-13

Similar Documents

Publication Publication Date Title
CN1240416C (en) Medicine for curing hypertension and its preparation method
CN1907386A (en) Chinese traditional medicinal composition for treating hyperlipemia, hypertension, and coronary disease
CN1289131C (en) Traditional Chinese medicine for treating appendicitis with high efficiency
CN1056309C (en) Medicine for curing angiocardiopathy and cerebrovascular disease
CN109692279A (en) A kind of Chinese medicine composition and preparation method thereof for treating parkinsonism
CN1418696A (en) Traditional Chinese medicine prepn. for treating cervical vertebra disease
CN1679639A (en) Oral soft capsule of medicinal preparation from blood-activating Chinese medicine pseudo-ginseng and leech extract
CN1123669A (en) Capsule for protecting liver and eliminating tumor
CN1050045C (en) Traditional Chinese medicine-Liu's Hua'ai huixiangdan for treating carcinoma of esophagus
CN1167429C (en) Medicine for treating cardiovascular disease
CN1772149A (en) Chinese medicine composition for treating coronary heart disease and its prepn
CN1045892C (en) Chinese medicine Guanxintong for preventing and curing coronary heart disease and angina pectoris, and producing process thereof
CN1178682C (en) Angiocardiopathy treating traditional Chinese medicine
CN1618439A (en) Broad-specturm medicine for treating snake venom poisoning
CN1132603C (en) Compound Wuduqing capsule of blister beetle
CN100346808C (en) Medicine for treating senile dementia and application of related Chinese medicinal composition
CN100366270C (en) Medicine for curing cardiovascular and cerebrovascular diseases
CN1328829A (en) Medicine for curing angiocardiopathy
CN1305510C (en) Medicine for treating intractable fever
CN1277559C (en) Medicine for treating rheumatism and its preparation
CN1092970C (en) Compound Chinese medicine for treating hepatocholepathy
CN106566760A (en) Fucoxanthin healthcare wine and preparation method thereof
CN1168483C (en) Heart disease treating medicine
CN1088801A (en) Chinese patent medicine Jinguanpian tablets and the method for making thereof of treatment insensitive impediment, particularly RA and AS
CN113713019A (en) Traditional Chinese medicine composition and application thereof in preparing medicine for treating thalassemia

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee